Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


26.11.2018

1 Curr Opin Obstet Gynecol
10 Gynecol Oncol
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Curr Opin Obstet Gynecol

  1. WASHINGTON C, Gunderson CC, Moore KN
    Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    Curr Opin Obstet Gynecol. 2018 Nov 15. doi: 10.1097/GCO.0000000000000507.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  2. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    PubMed     Text format     Abstract available

  3. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    PubMed     Text format     Abstract available

  4. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    PubMed     Text format     Abstract available

  5. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    PubMed     Text format     Abstract available

  6. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    PubMed     Text format     Abstract available

  7. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    PubMed     Text format     Abstract available

  8. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    PubMed     Text format     Abstract available

  9. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    PubMed     Text format     Abstract available

  10. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    PubMed     Text format     Abstract available

  11. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    PubMed     Text format     Abstract available


    PLoS One

  12. LIN ZP, Zhu YL, Lo YC, Moscarelli J, et al
    Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    PLoS One. 2018;13:e0207399.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: